Nira Ben-Jonathan

Summary

Affiliation: University of Cincinnati
Country: USA

Publications

  1. ncbi request reprint Dopamine as a prolactin (PRL) inhibitor
    N Ben-Jonathan
    Department of Cell Biology, Neurobiology, and Anatomy, University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA
    Endocr Rev 22:724-63. 2001
  2. pmc Effects of bisphenol A on adipokine release from human adipose tissue: Implications for the metabolic syndrome
    Nira Ben-Jonathan
    Department of Cancer and Cell Biology, University of Cincinnati, OH 45267, USA
    Mol Cell Endocrinol 304:49-54. 2009
  3. pmc What can we learn from rodents about prolactin in humans?
    Nira Ben-Jonathan
    Department of Cell and Cancer Biology, University of Cincinnati, Cincinnati, Ohio 45255, USA
    Endocr Rev 29:1-41. 2008
  4. ncbi request reprint Focus on prolactin as a metabolic hormone
    Nira Ben-Jonathan
    Department of Cell Biology, University of Cincinnati Medical School, Cincinnati, OH 45267 0521, USA
    Trends Endocrinol Metab 17:110-6. 2006
  5. pmc Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-alpha-positive and -negative breast cancer cells
    Elizabeth W LaPensee
    Department of Cancer and Cell Biology, University of Cincinnati, Cincinnati, Ohio 45267 0521, USA
    Environ Health Perspect 117:175-80. 2009
  6. ncbi request reprint Prolactin as an autocrine/paracrine growth factor in human cancer
    Nira Ben-Jonathan
    Department Cell Biology, University of Cincinnati Medical School, Cincinnati, OH 45267, USA
    Trends Endocrinol Metab 13:245-50. 2002
  7. pmc Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase
    Elizabeth W LaPensee
    Department of Cancer and Cell Biology, University of Cincinnati, Cincinnati, OH 45267 0521, USA
    Carcinogenesis 30:1298-304. 2009
  8. pmc Bisphenol A and estradiol are equipotent in antagonizing cisplatin-induced cytotoxicity in breast cancer cells
    Elizabeth W LaPensee
    Department of Cancer and Cell Biology, University of Cincinnati, OH 45267, USA
    Cancer Lett 290:167-73. 2010
  9. doi request reprint Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy
    Elizabeth W LaPensee
    Department of Cancer and Cell Biology, University of Cincinnati, Ohio 45267 0521, USA
    Endocr Relat Cancer 17:R91-107. 2010
  10. pmc Prolactin release by adipose explants, primary adipocytes, and LS14 adipocytes
    Eric R Hugo
    Department of Cell and Cancer Biology, University of Cincinnati, Cincinnati, Ohio 45267 0521, USA
    J Clin Endocrinol Metab 93:4006-12. 2008

Research Grants

  1. Prolactin as a Growth Factor in Breast Cancer
    Nira Ben Jonathan; Fiscal Year: 2007
  2. Xenoestrogens: Genomic and Non-genomic Mechanisms
    Nira Ben Jonathan; Fiscal Year: 2006
  3. NEONATAL EFFECTS AND METABOLISM OF XENOESTROGENS
    Nira Ben Jonathan; Fiscal Year: 2003
  4. Prolactin and Estrogens as Mitogens in Prostate Cancer
    Nira Ben Jonathan; Fiscal Year: 2002
  5. Prolactin as a Growth Factor in Breast Cancer
    Nira Ben Jonathan; Fiscal Year: 2010

Collaborators

  • Sanjay Kansra
  • Patrick Tso
  • J Wesley Alexander
  • Jessica G Woo
  • El Mustapha Bahassi
  • NELSON HORSEMAN
  • Eric M Jacobson
  • Nira Ben Jonathan
  • Elizabeth W LaPensee
  • Eric R Hugo
  • Christopher R LaPensee
  • Terry D Brandebourg
  • Jean Loftus
  • DANA C BORCHERDING
  • Karen Liby
  • Yuan Hung Lo
  • Eric Hugo
  • Sandy J Schwemberger
  • Keith S Gersin
  • Molly McFarland-Mancini
  • Robert Hnasko
  • Michael Zinger
  • Bonnie Neltner
  • Lisa Mohamet
  • Shao Chun Wang
  • Po Chun Ho
  • Min shan Chen
  • Anuradha De Silva
  • Gila Idelman
  • Nathan W Richtand
  • Sejal Fox
  • Scott Afton
  • Sandy Schwemberger
  • Scott E Afton
  • Sejal R Fox
  • Traci R Tuttle
  • Shamantha P Reddy
  • Jenna L Bown
  • Clay E S Comstock
  • Jeffrey J Sussman
  • Molly McFarland
  • Craig Burd
  • Lindsey Menchen

Detail Information

Publications28

  1. ncbi request reprint Dopamine as a prolactin (PRL) inhibitor
    N Ben-Jonathan
    Department of Cell Biology, Neurobiology, and Anatomy, University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA
    Endocr Rev 22:724-63. 2001
    ..The treatment of hyperprolactinemia has greatly benefited from the generation of progressively more effective and selective dopaminergic drugs...
  2. pmc Effects of bisphenol A on adipokine release from human adipose tissue: Implications for the metabolic syndrome
    Nira Ben-Jonathan
    Department of Cancer and Cell Biology, University of Cincinnati, OH 45267, USA
    Mol Cell Endocrinol 304:49-54. 2009
    ..The implications of these observations to the obesity-related metabolic syndrome and its sequelae are discussed...
  3. pmc What can we learn from rodents about prolactin in humans?
    Nira Ben-Jonathan
    Department of Cell and Cancer Biology, University of Cincinnati, Cincinnati, Ohio 45255, USA
    Endocr Rev 29:1-41. 2008
    ....
  4. ncbi request reprint Focus on prolactin as a metabolic hormone
    Nira Ben-Jonathan
    Department of Cell Biology, University of Cincinnati Medical School, Cincinnati, OH 45267 0521, USA
    Trends Endocrinol Metab 17:110-6. 2006
    ..Although the overall effects of PRL on body composition are modest and species specific, PRL might be involved in the manifestation of insulin resistance...
  5. pmc Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-alpha-positive and -negative breast cancer cells
    Elizabeth W LaPensee
    Department of Cancer and Cell Biology, University of Cincinnati, Cincinnati, Ohio 45267 0521, USA
    Environ Health Perspect 117:175-80. 2009
    ..In addition, the mechanism by which BPA exerts its biological actions is unclear. Although estrogen has been shown to antagonize anticancer drugs, the role of BPA in chemoresistance has not been examined...
  6. ncbi request reprint Prolactin as an autocrine/paracrine growth factor in human cancer
    Nira Ben-Jonathan
    Department Cell Biology, University of Cincinnati Medical School, Cincinnati, OH 45267, USA
    Trends Endocrinol Metab 13:245-50. 2002
    ..Establishment of PRL as an active participant in tumorigenesis should inspire the development of novel therapies aimed at reducing tumor growth by suppressing PRL production or by blocking its receptors...
  7. pmc Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase
    Elizabeth W LaPensee
    Department of Cancer and Cell Biology, University of Cincinnati, Cincinnati, OH 45267 0521, USA
    Carcinogenesis 30:1298-304. 2009
    ..Suppression of PRL production or blockade of its actions should benefit patients undergoing chemotherapy by allowing for lower drug doses and expanded drug options...
  8. pmc Bisphenol A and estradiol are equipotent in antagonizing cisplatin-induced cytotoxicity in breast cancer cells
    Elizabeth W LaPensee
    Department of Cancer and Cell Biology, University of Cincinnati, OH 45267, USA
    Cancer Lett 290:167-73. 2010
    ..Blockade of BPA and E2 actions should sensitize ER-negative breast tumors to anti-cancer drugs and allow for the inclusion of cisplatin in treatment regimens...
  9. doi request reprint Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy
    Elizabeth W LaPensee
    Department of Cancer and Cell Biology, University of Cincinnati, Ohio 45267 0521, USA
    Endocr Relat Cancer 17:R91-107. 2010
    ..Whereas PRL acts by activating the glutathione-S-transferase detoxification enzyme, E(2) and BPA act by inducing the antiapoptotic protein Bcl-2. The implications of these findings to patients undergoing chemotherapy are discussed...
  10. pmc Prolactin release by adipose explants, primary adipocytes, and LS14 adipocytes
    Eric R Hugo
    Department of Cell and Cancer Biology, University of Cincinnati, Cincinnati, Ohio 45267 0521, USA
    J Clin Endocrinol Metab 93:4006-12. 2008
    ..Prolactin (PRL) is a multifunctional hormone produced in humans by both pituitary and extrapituitary sites, including adipose tissue...
  11. pmc Selective estrogen receptor down-regulator and selective estrogen receptor modulators differentially regulate lactotroph proliferation
    Sanjay Kansra
    Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America
    PLoS ONE 5:e10060. 2010
    ..In this study our objective was to determine whether ERalpha degradation versus occupation, differentially modulates the biological outcome of anti-estrogens...
  12. ncbi request reprint The prolactin-deficient mouse has an unaltered metabolic phenotype
    Christopher R LaPensee
    Department of Cell Biology, University of Cincinnati, 3125 Eden Avenue, Ohio 45267 0521, USA
    Endocrinology 147:4638-45. 2006
    ..We conclude that PRL deficiency has negligible gross metabolic effects in mice...
  13. ncbi request reprint Induction of prolactin expression and release in human preadipocytes by cAMP activating ligands
    Molly McFarland-Mancini
    Department of Cell Biology, University of Cincinnati Medical School, Cincinnati, OH 45267 0521, USA
    Biochem Biophys Res Commun 344:9-16. 2006
    ..These data establish the transcriptional regulation of adipocyte PRL by the superdistal PRL promoter, its transient expression during adipogenesis, and the stimulatory effect of catecholamines and PACAP...
  14. pmc Dopamine receptors in human adipocytes: expression and functions
    DANA C BORCHERDING
    Department of Cancer and Cell Biology, University of Cincinnati, Cincinnati, Ohio, United States of America
    PLoS ONE 6:e25537. 2011
    ..The objective was to examine expression of DAR and ARSA in human adipose tissue and determine whether DA regulates prolactin (PRL) and adipokine expression and release...
  15. ncbi request reprint Prolactin regulation by heparin-binding growth factors expressed in mouse pituitary cell lines
    Robert Hnasko
    Department of Cell Biology, University of Cincinnati Medical School, Cincinnati, OH 45267, USA
    Endocrine 20:35-44. 2003
    ..The distinct heparin-binding factor that stimulates PRL gene transcription remains to be identified...
  16. ncbi request reprint Endostatin expression by MDA-MB-435 breast cancer cells effectively inhibits tumor growth
    Karen Liby
    Department of Cell Biology, University of Cincinnati Medical School, Ohio 45267 0521, USA
    Cancer Biol Ther 2:48-52. 2003
    ..0%) and showed a marked reduction in vascularization. In conclusion, expression of endostatin in MDA-MB-435 breast cancer cells effectively suppressed breast tumor growth by inhibiting angiogenesis and increasing apoptosis...
  17. ncbi request reprint Prolactin in breast and prostate cancer: molecular and genetic perspectives
    Eric M Jacobson
    Division of Endocrinology, Diabetes, and Metabolism, School of Medicine, University of Cincinnati, Ohio 45267, USA
    Discov Med 11:315-24. 2011
    ..This review discusses multiple features of the PRL signaling cascade and how they can be exploited in the search for effective therapies for patients with breast and prostate cancers...
  18. pmc Bisphenol A at environmentally relevant doses inhibits adiponectin release from human adipose tissue explants and adipocytes
    Eric R Hugo
    Department of Cell and Cancer Biology, University of Cincinnati, 3125 Eden Avenue, Cincinnati, OH 45267, USA
    Environ Health Perspect 116:1642-7. 2008
    ..Thus, any factor that suppresses adiponectin release could lead to insulin resistance and increased susceptibility to obesity-associated diseases...
  19. ncbi request reprint Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release
    Sanjay Kansra
    Department of Cell Biology, Neurobiology and Anatomy, University of Cincinnati College of Medicine, 3125 Eden Avenue, Cincinnati, OH 45267 0521, USA
    Mol Cell Endocrinol 239:27-36. 2005
    ..These data highlight the importance of studying the effects of anti-estrogens in multiple systems...
  20. pmc Insulin stimulates interleukin-6 expression and release in LS14 human adipocytes through multiple signaling pathways
    Christopher R LaPensee
    Department of Cancer and Cell Biology, University of Cincinnati School of Medicine, Cincinnati, Ohio 45267 0521, USA
    Endocrinology 149:5415-22. 2008
    ..Insulin-induced IL-6 gene expression is mediated by cGMP/cyclic GMP-dependent protein kinase/cAMP response element binding protein, whereas MAPK is involved in the insulin-stimulated IL-6 synthesis/release...
  21. pmc Prolactin upregulates its receptors and inhibits lipolysis and leptin release in male rat adipose tissue
    Terry D Brandebourg
    Department of Cell and Cancer Biology, University of Cincinnati College of Medicine, 3125 Eden Avenue, Cincinnati, OH 45267 0521, USA
    Biochem Biophys Res Commun 357:408-13. 2007
    ..This is the first demonstration of substantial effects of PRL on male adipocytes...
  22. ncbi request reprint Prolactin expression and secretion by human breast glandular and adipose tissue explants
    Michael Zinger
    Departments of Obstetrics and Gynecology, University of Cincinnati, College of Medicine, Cincinnati, Ohio 45267, USA
    J Clin Endocrinol Metab 88:689-96. 2003
    ..These data suggest an autocrine/paracrine role for PRL in human glandular and adipose breast tissue...
  23. ncbi request reprint LS14: a novel human adipocyte cell line that produces prolactin
    Eric R Hugo
    Department of Cell Biology, University of Cincinnati, Cincinnati, Ohio 45267 0521, USA
    Endocrinology 147:306-13. 2006
    ..The LS14 cells open up new avenues for research on human adipocyte biology and add to the repertoire of nonpituitary, PRL-producing cell lines...
  24. ncbi request reprint Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth
    Karen Liby
    Department of Cell Biology, University of Cincinnati Medical School, Cincinnati, OH 45267 0521, USA
    Breast Cancer Res Treat 79:241-52. 2003
    ..These data support a role for breast PRL as a growth/anti-apoptotic factor and suggest that it may serve as a novel therapeutic target for the treatment of breast cancer...
  25. pmc Phosphorylation at tyrosine 114 of Proliferating Cell Nuclear Antigen (PCNA) is required for adipogenesis in response to high fat diet
    Yuan Hung Lo
    Department of Cancer Biology, University of Cincinnati College of Medicine, 3125 Eden Avenue, Cincinnati, OH 45267 0521, USA
    Biochem Biophys Res Commun 430:43-8. 2013
    ..This study identifies a critical role for PCNA in adipose tissue development, and for the first time identifies a role of the core DNA replication machinery at the interface between proliferation and differentiation...
  26. pmc Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor
    Eric M Jacobson
    Division of Endocrinology, Diabetes and Metabolism, University of Cincinnati, Cincinnati, OH 45267 0567, USA
    Trends Endocrinol Metab 21:691-8. 2010
    ..Emphasis is placed on technological advances which enable high-throughput screening for small molecule inhibitors of PRLR signaling that could serve as oral medications...
  27. ncbi request reprint LS14 cells: a model for chemoresistance in liposarcoma
    Elizabeth W LaPensee
    Department of Cell and Cancer Biology, University of Cincinnati, Ohio 45267 0521, USA
    Cancer Biol Ther 6:519-24. 2007
    ..In conclusion, LS14 cells are much more resistant to chemotherapy than SW872 cells, making them an excellent model for exploring the efficacy and mechanism of action of anti-cancer drugs in liposarcomas...
  28. pmc Estrogen receptor-alpha mediates the epidermal growth factor-stimulated prolactin expression and release in lactotrophs
    Nira Ben-Jonathan
    Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    Endocrinology 150:795-802. 2009
    ..These results provide the first evidence that ErbB1-induced PRL release is ERalpha dependent...

Research Grants17

  1. Prolactin as a Growth Factor in Breast Cancer
    Nira Ben Jonathan; Fiscal Year: 2007
    ..Long Term Goal: To establish PRL as a mitogen/anti-apoptotic factor in breast cancer, serving as the foundation for the design of future breast cancer therapy. ..
  2. Xenoestrogens: Genomic and Non-genomic Mechanisms
    Nira Ben Jonathan; Fiscal Year: 2006
    ..The results of these studies should provide much needed experimental foundation for assessing the vulnerability of the pituitary gland to insults by endocrine disruptors. ..
  3. NEONATAL EFFECTS AND METABOLISM OF XENOESTROGENS
    Nira Ben Jonathan; Fiscal Year: 2003
    ..The results should provide a much needed experimental foundation for assessing the vulnerability of the neuroendocrine system to insults by environmental factors. ..
  4. Prolactin and Estrogens as Mitogens in Prostate Cancer
    Nira Ben Jonathan; Fiscal Year: 2002
    ..The findings on BPA may reveal the potential risk associated with human exposure to environmental estrogens. ..
  5. Prolactin as a Growth Factor in Breast Cancer
    Nira Ben Jonathan; Fiscal Year: 2010
    ..The long term goal is to establish FDA-approved, long acting dopamine agonists as suppressor or PRL secretion, resulting in increased efficacy of chemotherapeutic agents in breast cancer patients. ..